exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274636 RNA Name: hsa-miR-21-5p RNA Type: miRNA Chromosome: chr17 Starnd: + Coordinate: Start Site(bp): 59841273 End Site(bp): 59841294 External Links: hsa-miR-21-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand KAZN chr1 13892792 15118043 + UBE2T chr1 202331657 202341980 - CLEC2D chr12 9664969 9699553 + EIF4A2 chr3 186783205 186789897 + MGST1 chr12 16347142 16609259 + POLE3 chr9 113407235 113410675 - SOWAHC chr2 109614364 109618990 + OSER1 chr20 44195939 44210771 - EXOC4 chr7 133253073 134066589 + EDARADD chr1 236348257 236502915 + HNRNPA0 chr5 137745651 137754363 - GPSM3 chr6 32190766 32195523 - CTH chr1 70411218 70439851 + CITED2 chr6 139371807 139374648 - MTREX chr5 55307989 55425579 + AP3D1 chr19 2100988 2164468 - ELP2 chr18 36129444 36180557 + HSPA4 chr5 133052013 133106449 + RGS1 chr1 192575763 192580024 + HSD17B4 chr5 119452473 119637199 + ZFP36L1 chr14 68787660 68796253 - HMGA1 chr6 34236873 34246231 + EEF1B2 chr2 206159585 206162928 + DYNC1H1 chr14 101964573 102056443 + DUSP2 chr2 96143169 96145440 - MCRS1 chr12 49556544 49568145 - ATRX chrX 77504878 77786233 - ZADH2 chr18 75195113 75209139 - PLIN2 chr9 19108375 19149290 - TREX1 chr3 48465811 48467645 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC068768.1 chr12 123262060 123262402 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - OTUD6B-AS1 chr8 91059318 91070583 - SNHG1 chr11 62851984 62855953 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.